Pharmacovigilance and Risk Management Strategies Conference

Featured

Want to learn more about Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!

To keep you at the forefront.

Short Course 1:

Pharmacovigilance and Risk Management Planning

Short Course 2:

ICH E2C(R2)

Short Course 3:

FDA Adverse Event Reporting System (FAERS)

Short Course 1:

Pharmacovigilance and Risk Management Planning

Short Course 2:

ICH E2C(R2)

Short Course 3:

FDA Adverse Event Reporting System (FAERS)

Short Course 4:

FDA Pharmacovigilance Inspection Readiness

Stella Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP Strategy
Consultant, United Kingdom
James Wabby, MHS Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
AbbVie, United States
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Patient Safety Officer
Bristol-Myers Squibb Company, United States
E. Stewart Geary, MD MD, Global Safety Officer
Eisai Co., Ltd., Japan
Elizabeth E. Garrard, PharmD Executive Vice President, Global Safety Operations
Clinipace Worldwide, United States
Lisa Melanie Harinstein, PharmD Team Leader, Division of Pharmacovigilance, FDA
FDA, United States
Stephen Knowles, MD, MRCP Chief Medical Officer
Halozyme Therapeutics, United States
Robert L. Levin, MD Lead Medical Officer for Pharmacovigilance Strategy
FDA, United States
Michael Richardson, MD, FFPM, FRCP Senior Vice President, WorldWide Patient Safety
Bristol-Myers Squibb, United Kingdom
Annette Stemhagen, DrPH, PhD, FISPE Chief Science Officer
UBC, United States
Mick Foy Director of Delivery
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom